Compare Mercadolibre Inc (MELI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Mercadolibre Inc trades at $1,832.26 (market cap $95.11B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Mercadolibre Inc is far larger — about 12.6× Spyre Therapeutics Inc. Common Stock's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 118 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MELI | SYRE | |
|---|---|---|
Market Cap | $95.11B | $7.52B |
Volume | 242,115 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $108.92 |
52-Week Low | $1.55K | $22.18 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $102.76B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,839.11, down 2.82% on the day, amid a bullish technical setup and strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $28.89 billion, though net income margins have softened. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy services, while its fintech credit portfolio surged 75% in Q2 2026.
Outlook remains positive given dominant Latin American e-commerce and fintech positioning, but risks include macroeconomic pressures in key markets like Argentina and elevated valuation multiples. Wall Street consensus is strongly bullish with a $2,160 price target, though profit trends warrant monitoring for sustained shareholder returns.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
